Randomized controlled trial of deutetrabenazine for tardive dyskinesia the ARM-TD study

Neurology

Volumn 88, Issue 21, 2017, Pages 2003-2010

  Fernandez, Hubert H ^a   Factor, Stewart A ^b   Hauser, Robert A ^c   Jimenez Shahed, Joohi ^d   Ondo, William G ^e   Jarskog, L Fredrik ^f   Meltzer, Herbert Y ^g   Woods, Scott W ^h   Bega, Danny ^g   LeDoux, Mark S ⁱ   Shprecher, David R ^j,k   Davis, Charles ^l   Davis, Mat D ^m   Stamler, David ⁿ   Anderson, Karen E ^o  

^a LERNER RESEARCH INSTITUTE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k SUN HEALTH RESEARCH INSTITUTE   (United States)

^l CSD Biostatistics   (United States)

^m Teva Pharmaceutical Industries   (United States)

ⁿ Teva Pharmaceutical Industries   (United States)

^o GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; CYTOCHROME P450 2D6; DEUTETRABENAZINE; DIAZEPAM; HYDROXYZINE; OLANZAPINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; MUSCLE RELAXANT AGENT; TETRABENAZINE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; BARNES AKATHISIA SCALE; BIPOLAR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL DISEASE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOMNOLENCE; SUICIDAL IDEATION; TARDIVE DYSKINESIA; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; DOUBLE BLIND PROCEDURE; EUROPE; LEAST SQUARE ANALYSIS; MENTAL DISORDERS; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

COMORBIDITY; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MENTAL DISORDERS; MIDDLE AGED; NEUROMUSCULAR AGENTS; SEVERITY OF ILLNESS INDEX; TARDIVE DYSKINESIA; TETRABENAZINE; TREATMENT OUTCOME; UNITED STATES;

EID: 85019850856     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003960     Document Type: Article

References (23)

1. Aquino CCH, Lang AE. Tardive dyskinesia syndromes: Current concepts. Parkinsonism Relat Disord 2014;20 (suppl 1):S113-S117.
2. Tarsy D, Lungu C, Baldessarini RJ. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. In: William JW, Eduardo T, editors. Handbook of Clinical Neurology. Amsterdam, Netherlands: Elsevier; 2011:601-616.
3. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: Prospective cohort study. J Clin Psychiatry 2010; 71:463-474.
4. Samie MR, Dannenhoffer MA, Rozek S. Life-threatening tardive dyskinesia caused by metoclopramide. Mov Disord 1987;2:125-129.
5. Waln O, Jankovic J. An update on tardive dyskinesia: From phenomenology to treatment. Tremor Other Hyperkinetic Mov 2013;3:tre-03-161-4138-4131.
6. Jankelowitz SK. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat 2013;9:1371-1380.
7. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: Clinical recognition and management. Postgrad Med J 2011;87:132-141.
8. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: Treatment of tardive syndromes. Neurology 2013;81:463-469.
9. Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: Implications of the CATIE schizophrenia trial. Neurol Clin 2011; 29:127-148.
10. Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: Therapeutic options for an increasingly common disorder. Neurotherapeutics 2014;11:166-176.
11. Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a University-based movement disorder clinic. Tremor Other Hyperkinetic Mov 2014;4:266.
12. Rana AQ, Chaudry ZM, Blanchet PJ. New and emerging treatments for symptomatic tardive dyskinesia. Drug Des Devel Ther 2013;7:1329-1340.
13. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 2006;66:366-372.
14. XENAZINE Prescribing Information. Deerfield, IL: Lundbeck; 2015.
15. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010;8:331-373.
16. Shao L, Hewitt MC. The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect 2010; 23:398-404.
17. Stamler D, Bradbury M, Brown F. The pharmacokinetics and safety of deuterated-tetrabenazine. Neurology 2013; 80:P07.210.
18. Timmins GS. Deuterated drugs: Where are we now? Expert Opin Ther Patents 2014;24:1067-1075.
19. Huntington Study Group, Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. JAMA 2016;316:40-50.
20. Epping EA, Kim JI, Craufurd D, et al. Longitudinal psychiatric symptoms in prodromal Huntington's disease: A decade of data. Am J Psychiatry 2016;173:184-192.
21. Casey DE. Tardive dyskinesia. West J Med 1990;153: 535-541.
22. Rittmannsberger H. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics. Psychiatr Danub 2008;20:461-465.
23. Haidet KK, Tate J, Divirgilio-Thomas D, Kolanowski A, Happ MB. Methods to improve reliability of videorecorded behavioral data. Res Nurs Health 2009;32: 465-474.